| Eli Lilly Touts Antibody Treatments for Preventing COVID in Nursing Homes | <p>Eli Lilly and Company on Jan. 21 said its neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 infections at nursing homes in its latest trial, called the BLAZE-2 trial, reducing risk by up to 80 percent for residents.</p><p>In a statement, the company said Bamlanivimab significantly cut the risk of contracting symptomatic COVID-19 among residents and staff of long term care facilities. The antibody treatment is not a vaccine for COVID-19, but a treatment.</p><p>“The Phase 3 BLAZE-2 COVID-19 prevention trial—conducted in partnership with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the COVID-19 Prevention Network—enrolled residents and staff at skilled nursing and assisted living facilities,” Eli Lilly said.</p><p>In total, 965 participants tested negative for the SARS-CoV-2 virus at baseline (299 residents and 666 staff), while132 participants (41 residents and 91 staff) tested positive for the virus, adding to the growing body of evidence for treatment with bamlanivimab, the company said.<br>All participants were randomized to receive either 4,200 mg of bamlanivimab or placebo.</p><p>After all participants reached eight weeks of follow-up, there was a significantly lower frequency of symptomatic COVID-19 (the primary endpoint) in the bamlanivimab treatment arm versus placebo.</p><p>In addition, Eli Lilly said for the prespecified subgroup of just nursing home residents (no staff), there was also a significantly lower frequency of symptomatic COVID-19 in those treated with bamlanivimab versus placebo. </p><p>“These results suggest that residents randomized to bamlanivimab have up to an 80 percent lower risk of contracting COVID-19 versus residents in the same facility randomized to placebo,” the company said.</p><p>Results from exploratory analyses of viral load in the treatment group were consistent with previously disclosed data from BLAZE-1 evaluating bamlanivimab as an outpatient treatment for recently diagnosed COVID-19.</p><p>Eli Lilly said among the 299 residents in the prevention group, there were four deaths attributed to COVID-19, and all occurred in the placebo arm. There were no COVID-19 attributed deaths in the bamlanivimab arm. Over the entire trial, there were a total of 16 deaths reported, including deaths not related to COVID-19, and all deaths were residents (11 deaths in placebo arm and five in bamlanivimab arm).</p><p>“We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society,” said Daniel Skovronsky, MD, PhD, Lilly's chief scientific officer and president of Lilly Research Laboratories. </p><p>“These data provide important additional clinical evidence regarding the use of bamlanivimab to fight COVID-19 and strengthen our conviction that monoclonal antibodies such as bamlanivimab can play a critical role in turning the tide of this pandemic.”</p><p>An independent data and safety monitoring board oversaw the BLAZE-2 trial. In the trial, the safety profile of bamlanivimab was consistent with observations from the Phase 1 and Phase 2 trials. Serious adverse events were reported at a similar frequency in the bamlanivimab and placebo groups. </p><p>Across multiple clinical trials, Lilly now has collected safety and efficacy data in more than 4,000 patients treated with bamlanivimab, either alone or administered together with another antibody.</p><p>Bamlanivimab is authorized for emergency use by the Food and Drug Administration for the treatment of mild to moderate COVID-19 in high-risk patients. Visit <a href="https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients">combatcovid.hhs.gov </a>to find out more about antibody therapy.<br></p> | 2021-01-22T05:00:00Z | <img alt="" src="/Breaking-News/PublishingImages/740%20x%20740/0120_News4.jpg" style="BORDER:0px solid;" /> | COVID-19 | Patrick Connole | Trial found new agent significantly cut risk of contracting COVID-19 among residents, staff in long term care facilities. |
| AHCA, NCAL Ready to Work With New President, Congress on LTC Solutions | <p>The American Health Care Association/National Center for Assisted Living (AHCA/NCAL) congratulated President Joe Biden and Vice President Kamala Harris on their inauguration into office, declaring the long term and post-acute care profession is ready to work with the new administration and Congress to find solutions to issues like COVID-19 vaccine distribution.</p><p>“We congratulate President Joe Biden and Vice President Kamala Harris on their inauguration, and we look forward to working with the new administration and 117th Congress to develop meaningful solutions for the challenges long term care providers face—many of which have been magnified by the pandemic,” said Mark Parkinson, president and chief executive officer of AHCA/NCAL.</p><p>“There is still an immediate crisis in front of us. Long term care providers are working with pharmacies and state officials to help administer life-saving vaccines swiftly to residents and staff, and we are hopeful we have reached a turning point in our fight against the virus,” he said. <br>However, with record-breaking numbers of COVID cases among the general population and in long term care facilities, “we cannot let our guard down,” Parkinson said. </p><p>“Lawmakers must continue to ensure that long term care facilities are made a priority for the resources they need to protect our most vulnerable citizens and our health care heroes on the frontlines.”</p><p>At the same time, the nursing care profession must reflect on the lessons learned throughout the pandemic and apply them toward strengthening the health care system. </p><p>“We will work collaboratively with the Biden Administration and members of Congress to achieve our goals and create a better future for our nation’s seniors," Parkinson said.<br></p> | 2021-01-20T05:00:00Z | <img alt="" src="/Breaking-News/PublishingImages/740%20x%20740/white_house_3.jpg" style="BORDER:0px solid;" /> | COVID-19 | Patrick Connole | Association leader says there is still a crisis, with record-breaking numbers of COVID cases among the general population and within the facilities. |
| Fourth Quarter 2020 Sees Record Low Occupancy for Senior Housing | <p>Senior housing occupancy decreased 1.3 percentage points in the fourth quarter of 2020 to 80.7 percent, a record low, according to new data from NIC MAP® Data Service (NIC MAP) provided by the National Investment Center for Seniors Housing & Care (NIC).</p><p>Since the first quarter of 2020 when the COVID-19 pandemic began, occupancy fell by 6.8 percentage points.</p><p>“Senior housing occupancy declines were less pronounced in the fourth quarter than the previous two quarters, though the fourth quarter decline is still quite large from a historic perspective,” said NIC’s chief economist, Beth Burnham Mace. “The surge in COVID-19 cases following Thanksgiving and Christmas suggests further disruption lies ahead. That said, the recent distribution of the vaccines should soon provide some relief.”</p><p>NIC data show large disparities between occupancy rates across metropolitan markets. For instance, San Jose, Calif. (88.5 percent), San Francisco (86.9 percent), and Seattle (84.8 percent) had the highest occupancy rates of the 31 metropolitan markets that make up NIC MAP’s Primary Markets, while Houston (73.5 percent), Cleveland (76.6 percent), and Miami (76.7 percent) recorded the lowest.</p><p>NIC said assisted living occupancy fell 1.3 percentage points to 77.7 percent in the fourth quarter, and independent living occupancy dropped 1.4 percentage points to 83.5 percent. Since March, assisted living and independent living occupancy have fallen by 7.4 and 6.2 percentage points, respectively.</p><p>“The COVID-19 pandemic has impacted move-ins and move-outs across senior living properties,” said Chuck Harry, chief operating officer of NIC. “Move-ins slowed as operators enacted moratoriums to keep residents safe and as safety protocols limited new leasing activity, while move-outs have been affected as residents moved to higher-acuity care settings.”</p><p>Separately, inventory growth slowed sharply for assisted living with 1,626 units added in the Primary Markets, the fewest since the third quarter of 2013.</p><p><a href="https://info.nic.org/nic-map-4q20-market-fundamentals">Click here </a>for the Market Fundamentals report.</p> | 2021-01-14T05:00:00Z | <img alt="" src="/Breaking-News/PublishingImages/740%20x%20740/0920_News1.jpg" style="BORDER:0px solid;" /> | | Patrick Connole | NIC data show large disparities between occupancy rates across metropolitan markets. |
| Telehealth a Silver Lining in Pandemic | <p><span></span>Since the pandemic began, telehealth services—specifically meeting with physicians online—have been a time saver for one Massachusetts provider. In "The Telehealth Phenomenon," learn how providers have made changes to protect residents and keep care running smoothly, learning lessons and seeing benefits along the way. To read more, go to <em>Provider's </em>just<em> </em>released first digital issue <a href="https://pagepro.mydigitalpublication.com/publication/?m=63330&i=687740&p=1">here.</a></p><p></p> | 2021-01-12T05:00:00Z | <img alt="" src="/Monthly-Issue/2021/January/PublishingImages/telehealth-0121.jpg" style="BORDER:0px solid;" /> | COVID-19;Caregiving | Amy Mendoza | In its first ever digital issue, Provider reports on how COVID-19 has changed the supply and demand of telehealth services in long term and post-acute care. |